Literature DB >> 28918688

Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia.

Lara Rizzotto1, Tzung-Huei Lai1, Arianna Bottoni1, Jennifer A Woyach1, Rosa Lapalombella1, Clara D Bloomfield2, John C Byrd1, Deepa Sampath1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28918688      PMCID： PMC6029688          DOI： 10.1080/10428194.2017.1376742

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  9 in total

1.  Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.

Authors:  H Wu; C Hu; A Wang; E L Weisberg; W Wang; C Chen; Z Zhao; K Yu; J Liu; J Wu; A Nonami; L Wang; B Wang; R M Stone; S Liu; J D Griffin; J Liu; Q Liu
Journal:  Leukemia       Date:  2015-07-03       Impact factor: 11.528

Review 2.  Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.

Authors:  A Quintás-Cardama; F P S Santos; G Garcia-Manero
Journal:  Leukemia       Date:  2010-11-30       Impact factor: 11.528

3.  FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation.

Authors:  Thomas Oellerich; Sebastian Mohr; Jasmin Corso; Julia Beck; Carmen Döbele; Helene Braun; Anjali Cremer; Silvia Münch; Johannes Wicht; Mark F Oellerich; Gesine Bug; Hanibal Bohnenberger; Christina Perske; Ekkehard Schütz; Henning Urlaub; Hubert Serve
Journal:  Blood       Date:  2015-01-20       Impact factor: 22.113

4.  Targeting BTK through microRNA in chronic lymphocytic leukemia.

Authors:  Arianna Bottoni; Lara Rizzotto; Tzung-Huei Lai; Chaomei Liu; Lisa L Smith; Rose Mantel; Sean Reiff; Dalia El-Gamal; Karilyn Larkin; Amy J Johnson; Rosa Lapalombella; Amy Lehman; William Plunkett; John C Byrd; James S Blachly; Jennifer A Woyach; Deepa Sampath
Journal:  Blood       Date:  2016-10-17       Impact factor: 22.113

5.  Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

Authors:  Guillermo Garcia-Manero; Hui Yang; Carlos Bueso-Ramos; Alessandra Ferrajoli; Jorge Cortes; William G Wierda; Stefan Faderl; Charles Koller; Gail Morris; Gary Rosner; Andrey Loboda; Valeria R Fantin; Sophia S Randolph; James S Hardwick; John F Reilly; Cong Chen; Justin L Ricker; J Paul Secrist; Victoria M Richon; Stanley R Frankel; Hagop M Kantarjian
Journal:  Blood       Date:  2007-10-25       Impact factor: 22.113

6.  Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.

Authors:  Guillermo Garcia-Manero; Francesco Paolo Tambaro; Nebiyou B Bekele; Hui Yang; Farhad Ravandi; Elias Jabbour; Gautam Borthakur; Tapan M Kadia; Marina Y Konopleva; Stefan Faderl; Jorge E Cortes; Mark Brandt; Yumin Hu; Deborah McCue; Willie Mae Newsome; Sherry R Pierce; Marcos de Lima; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

Review 7.  MicroRNAs: target recognition and regulatory functions.

Authors:  David P Bartel
Journal:  Cell       Date:  2009-01-23       Impact factor: 41.582

8.  Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML.

Authors:  Lyubov Zaitseva; Megan Y Murray; Manar S Shafat; Matthew J Lawes; David J MacEwan; Kristian M Bowles; Stuart A Rushworth
Journal:  Oncotarget       Date:  2014-10-30

9.  Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.

Authors:  Stuart A Rushworth; Megan Y Murray; Lyubov Zaitseva; Kristian M Bowles; David J MacEwan
Journal:  Blood       Date:  2013-12-04       Impact factor: 22.113
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.